Seventy percent of participants rated total symptom clearance as very important—higher than any other treatment attribute, including speed of response or convenience. How does this align with what dermatologists have traditionally defined as treatment success?
A retrospective analysis comparing 3-year psoriatic arthritis incidence across immunomodulatory classes finds an emerging signal favoring IL-23 pathway agents—a finding with meaningful implications for treatment selection in patients at risk for joint disease.
An analysis of the POSITIVE study showed that tildrakizumab not only clears skin but substantially reduces itch, pain, and fatigue, with psychological well-being scores ultimately surpassing general population norms by year 2.
The POSITIVE study's 2-year real-world data confirm that tildrakizumab drives near-total skin clearance and sustained improvement in difficult-to-treat areas, lending important practical validity to the phase 3 trial results.
A phase 3b trial demonstrates that tildrakizumab meets robust efficacy endpoints for nail psoriasis—an historically difficult manifestation to treat—while maintaining a favorable long-term safety profile through week 72.
